The Development of a Korean Modification of the Scale to Measure Subjective Well-Being under Neuroleptic Treatment (KmSWN).
- Author:
Jin Sang YOON
1
;
Seung Hee KOOK
;
Hyung Young LEE
;
Chul LEE
;
In Ho PAIK
Author Information
1. Department of Neuropsychiatry, College of Medicine, Chonnam National University, Kwangju, Korea.
- Publication Type:Original Article
- Keywords:
KmSWN;
Subjective well-being;
Neuroleptic treatment;
Schizophrenia;
GHQ/QL-12
- MeSH:
Antipsychotic Agents;
Compliance;
Dyskinesias;
Hospitalization;
Humans;
Outpatients;
Parkinsonian Disorders;
Quality of Life;
Reproducibility of Results;
Schizophrenia;
Statistics as Topic
- From:Journal of Korean Neuropsychiatric Association
2000;39(6):987-998
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVES: The purpose of this study was to develop the Korean modification of SWN (KmSWN), based on the original 38-item SWN (a self-rating scale to measure subjective well-being under neuroleptic treatment) by Naber et. al. in 1994, but containing the reduced number of items and the modified content. METHODS: The KmSWN with 22 items and General Health Questionnaire/Quality of Life-12 (GHQ /QL-12) were administered to 204 out-patients with schizophrenia. Also, their sociodemographic and clinical characteristics were investigated. Data analyses were conducted based on 176 patients whose responses to the scale, as well as whose related informations, were reliable. First, the reliability and validity of KmSWN were assessed comprehensively. Second, the relationships between the total score of KmSWN and the sociodemographic and clinical characteristics were examined. Finally, in order to identify the predictable variables on the total score of KmSWN, the stepwise multiple regression analysis was conducted, where the independent variables were already shown significant correlations with the total score of KmSWN. RESULTS: Three of 22 items of KmSWN were excluded from the following analysis due to their poor internal consistency. KmSWN comprised with 19 items (KmSWN-19) showed high levels of spilthalf reliability (.91), mean of interitem correlations (.38) and internal consistency (Cronbach alpha .92). Factor analysis of the KmSWN-19 revealed that a three-factor solution accounted for 100% of total explained variance. The three factors were interpreted as 'dissatisfaction', 'physical and mental functioning', 'emotional regulation and self-control'. The concurrent validity of KmSWN-19 with GHQ/QL-12 was very high (-.83). Of the sociodemographic and clinical characteristics, age, disposable money, socioeconomic level, number of previous hospitalizations, compliance with medication and satisfaction with medication were positively correlated with the total score of KmSWN-19, while severity of illness, severity of parkinsonism, severity of dyskinesia, administration frequency of medication and omission number of medication were negatively correlated. However, the total score of KmSWN-19 was not correlated with the class and the dose of neuroleptics. In stepwise multiple regression analysis, the satisfaction with medication, the omission number of medication and the disposable money were significantly contributed to the total score of KmSWN-19, and they explained 24% of the variance. CONCLUSIONS: The above findings indicated that KmSWN-19 was a reliable, valid and practical self-rating scale to measure subjective well-being in out-patients with schizophrenia. Moreover, KmSWN-19 seemed to be a general scale applicable to all the schizophrenic or other psychotic patients if they were able to complete it, rather than a specific scale only for the patients undergoing the neuroleptic treatment. Based on the results of the predictable variables on the total score of KmSWN-19, one may argue that intraindividual characteristics such as value, belief and personality traits, although they were not evaluated in this study, should be considered in assessing subjective well-being or the quality of life.
